Outcomes and susceptibility to neuraminidase inhibitors in individuals infected with different Influenza B Lineages: The influenza resistance information study

Journal of Infectious Diseases

Volumn 213, Issue 2, 2016, Pages 183-190

  Van Der Vries, Erhard ^a,f   Ip, Dennis K M ^b   Cowling, Benjamin J ^b   Zhang, Jitao D ^c   Tong, Xiao ^d,g   Wojtowicz, Krzysztof ^e,h   Schutten, Martin ^a   Boucher, Charles A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

^e Micron Research Ltd   (United Kingdom)

^f UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^g InnovaTID   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

antiviral; IC50; influenza B; lineage; neuraminidase inhibitor; outcomes; resistance; susceptibility; Victoria; Yamagata

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; OSELTAMIVIR;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG SENSITIVITY; FEMALE; FEVER; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; IC50; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA B VIRUS (B/VICTORIA); INFLUENZA B VIRUS (B/YAMAGATA); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; VIRAL CLEARANCE; VIRUS GENE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CLASSIFICATION; DRUG EFFECTS; GENETICS; INFANT; INFLUENZA, HUMAN; MIDDLE AGED; PRESCHOOL CHILD; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HUMANS; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; YOUNG ADULT; ZANAMIVIR;

EID: 84959883597     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv375     Document Type: Article

References (20)

1. McCullers JA, Hayden FG. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 2012; 205:870-2.
2. Su S, Chaves SS, Perez A, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis 2014; 59:252-5.
3. Centers for Disease Control and Prevention. Influenza-Associated pediatric deaths-United States, September 2010-August 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1233-8.
4. Centers for Disease Control and Prevention. Use of Antivirals: Background and Guidance on the Use of Influenza Antiviral Agents. http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm. Accessed 7 January 2015.
5. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Part I: recommendations. http://www.who.int/csr/resources/publications/swineflu/h1n1-use-Antivirals-20090820/en/. Accessed 7 January 2015.
6. SamsonM, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98:174-85.
7. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59-68.
8. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013; 56:1197-205.
9. Fujisaki S, Takashita E, Yokoyama M, et al. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 2012; 429:51-6.
10. Jackson D, BarclayW, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005; 55:162-9.
11. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-20.
12. Wang D, Sleeman K, Huang W, et al. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 2013; 97:240-4.
13. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced susceptibility to neuraminidase inhibitors. JAMA 2007; 297:1435-42.
14. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284-92.
15. Garg S, Moore Z, Lee N, et al. A cluster of patients infected with I221V influenza B virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011. J Infect Dis 2013; 207:966-73.
16. Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 2011; 17:2043-6.
17. Carr S, Ilyushina NA, Franks J, et al. Oseltamivir-resistant influenza A and B viruses pre- and post antiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 2011; 30:284-8.
18. Socan M, Prosenc K, Ucakar V, Berginc N. A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J Clin Virol 2014; 61:156-60.
19. Tan Y, Guan W, Lam TT, et al. Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009-2010. J Virol 2013; 87: 12447-56.
20. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 2013; 100:520-3.